Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Flux Power Holdings Inc (FLUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Flux Power Holdings Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.72 (market cap $8.04B), while Flux Power Holdings Inc trades at $0.72 (market cap $15.57M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 516.4× Flux Power Holdings Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BIO | FLUX | |
|---|---|---|
Market Cap | $8.04B | $15.57M |
Sector | Health | Utilities |
52-Week High | $339.75 | $6.66 |
52-Week Low | $241.71 | $0.72 |
Enterprise Value | $7.85B | $21.74M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
FLUX trades at $0.7304, down 5.94% in the last session, with a bearish technical signal from moving averages. The company reported mixed quarterly results, missing Q3 2026 EPS estimates but beating in Q4 2025. Revenue declined from $66M in 2025 to $51M in 2026, with negative net income margins persisting. Recent developments include the launch of SkyEMS 3.0 AI-powered fleet management software and new executive appointments aimed at growth acceleration.
Despite unanimous analyst buy ratings, FLUX faces significant profitability challenges with negative ROE and ROA. The stock's primary investment opportunity lies in its clean energy technology positioning and strong analyst support, but risks include ongoing losses, revenue contraction, and competitive pressures in the energy storage market that could limit near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →
